SYRS vs. CUE, PGNX, YMAB, AVTE, SIGA, FULC, TRDA, ALT, PEPG, and CYRX
Should you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include Cue Biopharma (CUE), Progenics Pharmaceuticals (PGNX), Y-mAbs Therapeutics (YMAB), Aerovate Therapeutics (AVTE), SIGA Technologies (SIGA), Fulcrum Therapeutics (FULC), Entrada Therapeutics (TRDA), Altimmune (ALT), PepGen (PEPG), and Cryoport (CYRX).
Cue Biopharma (NASDAQ:CUE) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, community ranking, valuation, analyst recommendations, institutional ownership, earnings and risk.
In the previous week, Cue Biopharma and Cue Biopharma both had 1 articles in the media. Syros Pharmaceuticals' average media sentiment score of 1.88 beat Cue Biopharma's score of 1.67 indicating that Cue Biopharma is being referred to more favorably in the media.
Cue Biopharma has a net margin of -711.84% compared to Cue Biopharma's net margin of -1,656.34%. Syros Pharmaceuticals' return on equity of -128.30% beat Cue Biopharma's return on equity.
Cue Biopharma has higher earnings, but lower revenue than Syros Pharmaceuticals. Cue Biopharma is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Cue Biopharma presently has a consensus target price of $8.00, suggesting a potential upside of 440.54%. Syros Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 171.84%. Given Syros Pharmaceuticals' higher possible upside, analysts plainly believe Cue Biopharma is more favorable than Syros Pharmaceuticals.
Cue Biopharma has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500.
35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 7.5% of Cue Biopharma shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Syros Pharmaceuticals received 218 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 63.89% of users gave Syros Pharmaceuticals an outperform vote while only 51.81% of users gave Cue Biopharma an outperform vote.
Summary
Cue Biopharma beats Syros Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Syros Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syros Pharmaceuticals Competitors List
Related Companies and Tools
